SS-31

ASSUMED based on in vitro and animal data, partially supported in human disease populations. SS-31 is a cell-penetrating tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that concentrates ~1000-fold in the inner mitochondrial membrane via electrostatic and hydrophobic interactions. Once localized, it binds cardiolipin, a phospholipid critical for cristae architecture and electron transport chain supercomplex assembly. By stabilizing cardiolipin, SS-31 is theorized to preserve mitochondrial membrane potential, improve electron transfer efficiency, reduce reactive oxygen species production at complexes I and III, and support ATP synthesis. Whether this translates to meaningful functional improvement in humans without mitochondrial pathology is not established.

Failed trials still count toward the letter: MMPOWER-3, PROGRESS-HF and EMBRACE-STEMI were randomized and missed their main endpoints, and each result is shown in its own tag.

• FDA approved for one ultra-rare cardiolipin disorder (Barth syndrome, Sept 2025), but the 218-person Phase 3 trial for the broader mitochondrial myopathy population missed both primary endpoints at 24 weeks.
• The mechanism is the most solid part of the story: it really does bind cardiolipin in the inner mitochondrial membrane in biochemical studies, and cardiolipin really does matter for electron transport chain efficiency.
• Published trials used 40 mg a day (and one 4 mg arm in heart failure), and the main trials in disease did not beat placebo. No verified dose statement exists for healthy users.

Adverse events

Injection site reactions are the dominant adverse event: 12 of 12 Barth patients (100 percent) versus 8 of 12 on placebo in the label trial, and up to 86% of elamipretide-treated participants vs 71% placebo in ReCLAIM-2. Reactions include pruritus, pain, bruising, and erythema at the injection site. Mild headache and nausea reported in a minority. The approved label warns of hypersensitivity reactions, including serious allergic reactions needing emergency treatment (rash, eczematous dermatitis, cough), which can appear within minutes to months of starting. Eosinophil counts rise for about 3 months and settle by 6 to 12 months. Published Phase 1/2 trials (MMPOWER-3, TAZPOWER, PROGRESS-HF, EMBRACE-STEMI, ReCLAIM-2) reported no deaths and no other serious systemic effects attributed to the drug. ECG, vital signs, and serum chemistry showed no clinically significant changes attributable to elamipretide across trials. 168-week TAZPOWER OLE added no new safety signals.

Contraindications

The label contraindicates anyone with a prior serious hypersensitivity reaction to elamipretide. It is not approved for neonates (the vial contains benzyl alcohol) or for intravenous use. Use in pregnancy, lactation, and severe renal or hepatic failure is not well characterized. Compounded peptide sources carry additional sterility and purity risks not present in the pharmaceutical formulation.

Theoretical concerns

Cardiolipin modulation affects multiple mitochondrial processes including apoptosis signaling; theoretical concern that systemic cardiolipin stabilization could interfere with normal programmed cell death in rapidly dividing cells (immune cells, gut epithelium). Not observed in trials to date but long-term data beyond 4 years is limited even in disease populations.

What nobody knows yet

Long-term effects (beyond 3-4 years) in humans are unknown. Effects in healthy adults with normal mitochondrial function are not studied. Optimal dosing, cycling, and duration for any off-label purpose are entirely undefined by controlled data. A 2026 rodent HFpEF study found mechanistic improvement in mitochondrial respiration that did not translate into functional cardiac benefit, raising the question of whether the mechanism alone is sufficient to produce clinical endpoints in established disease states.

What else could explain the result

Wellness users who report energy and recovery improvements are almost always also on TRT, GLP-1 agonists, or peptide stacks (BPC-157, CJC-1295, TB-500). TRT alone substantially improves mitochondrial density and energy. GLP-1 agonists reduce inflammatory fat mass which improves baseline energy. Stacking SS-31 on top of these makes attribution essentially impossible. Community reports should be read with this baseline-effect lens.

Is the vial what it says?

Compiled from the cited sources below. Where no completed human trial exists, the grade says so.

Half-life and storage

Half-life: Approximately 2 hours plasma half-life after subcutaneous injection, based on pharmacokinetic data from Phase 1 dose-escalation study. Mitochondrial dwell time may exceed plasma half-life due to preferential accumulation in mitochondrial membrane.

Once mixed: Lyophilized SS-31 is relatively stable if stored frozen and protected from light. Reconstituted solution should be used within 24 hours if refrigerated; not validated for extended storage after reconstitution. The dipeptide tyrosine analog (2-prime-6-prime-dimethyltyrosine) is susceptible to oxidation; antioxidant-free reconstitution with bacteriostatic water is the standard practice in compounded formulations.

Case study

• SS-31: the vial I kept too long RunningThe compound was fine. My handling of it was not. A mixed vial sat in the fridge for two and a half months.

What people report

Volume of reports: mixed. Reports exist but contradict each other.

Moderate community discussion in longevity and biohacker forums (Reddit r/Peptides, Longecity, various wellness blogs). Volume has grown significantly since FDA approval in 2025 gave it mainstream legitimacy.

Inconsistent. Reports of improved energy and recovery are common but highly variable. A subset of users report nothing. The pattern mirrors what you would expect from a peptide with a real mechanism but uncertain human efficacy outside specific disease states.

Low to moderate. Most community reports come from people also on TRT or other compounds. No n-of-1 well-controlled biohacker reports exist. The clinical trial failure in PMM patients (a population with actual mitochondrial dysfunction) suggests healthy-user effects are likely smaller or absent.

• Anecdote: users commonly report a subtle but noticeable increase in stamina and reduced workout recovery time within 2 to 4 weeks, though this is nearly impossible to separate from concurrent TRT or BPC-157 use.
• Anecdote: a subset of biohacker forum users report no perceptible effect at the low doses they use, consistent with the clinical trial fatigue data showing no separation from placebo even at 40 mg/day in disease populations.
• Anecdote: several long-term users (6+ months) describe subjective cognitive clarity improvements, which is not a studied endpoint in any trial and is highly susceptible to expectation effect.
• Anecdote: injection site itching and mild redness lasting 30 to 60 minutes is reported by a majority of community users who inject subcutaneously, matching the clinical trial adverse event profile closely.

Reports are anecdote, not proof.

Can you tell if it is working?

First documented human use: Circa 2013-2015, Phase I/II dose-escalation safety study in adults with primary mitochondrial myopathy, sponsored by Stealth BioTherapeutics. The trial number NCT01786941 and the 2010 start date cited in some sources could not be independently confirmed against the ClinicalTrials.gov registry and should be treated as unverified; the SPIMM-201 Phase 1/2 IV-dose study is the earliest published human dataset.

1. Early 2000sDrs. Hazel Szeto and Peter Schiller at Cornell University develop the SS peptide series (Szeto-Schiller), identifying SS-31 as a cell-penetrating tetrapeptide that selectively accumulates in mitochondria via cardiolipin binding.
2. 2006Hazel Szeto founds Stealth BioTherapeutics to advance SS-31 (initially called Bendavia, later MTP-131) toward clinical development.
3. 2016EMBRACE-STEMI Phase 2a trial (PMID 26586786) published in European Heart Journal: IV elamipretide in first-time anterior STEMI patients undergoing PCI found no decrease in myocardial infarct size vs placebo.
4. 2018-2023Phase 1/2 MMPOWER study shows early promise in mitochondrial myopathy. Phase 3 MMPOWER-3 enrolls 218 patients; results released 2023 show failure on both primary endpoints (6-minute walk test and fatigue scale).
5. 2020PROGRESS-HF Phase 2 trial (PMID 32068002) published in Journal of Cardiac Failure: 71 HFrEF patients randomized to placebo, 4 mg, or 40 mg elamipretide for 28 days; no significant improvement in left ventricular end-systolic volume at 4 weeks.
6. September 2025FDA grants accelerated approval to FORZINITY (elamipretide HCl) for Barth syndrome in patients weighing at least 30 kg, the first FDA-approved mitochondria-targeted therapeutic. Approval rests on knee extensor strength, an intermediate endpoint; continued approval contingent on confirmatory trial results.
7. July 2026The randomized confirmatory trial 4TAZPower (NCT07531251, Phase 4) begins recruiting.

• FORZINITY prescribing information (DailyMed)(Primary source for dose, warnings, contraindications and clinical-study text.)
• FDA press announcement: Accelerated Approval for Barth Syndrome (September 2025)(Official FDA announcement confirming September 2025 accelerated approval of FORZINITY for Barth syndrome; notes approval contingent on confirmatory trial.)
• MMPOWER-3 Phase 3 RCT full paper (PMC10382259, Neurology 2023)(218-patient placebo-controlled trial; both primary endpoints (6MWT and PMMSA fatigue) failed to reach statistical significance. Key paper for calibrating efficacy expectations.)
• Elamipretide structure, mechanism, and therapeutic potential review (PMC11816484, IJMS 2025)(Peer-reviewed comprehensive review covering cardiolipin binding mechanism, cristae stabilization, and overview of human trial landscape through 2024.)
• ReCLAIM-2 Phase II AMD trial (PMC11599447, Ophthalmology Science 2024)(Phase II placebo-controlled trial in dry AMD geographic atrophy showing surrogate endpoint (ellipsoid zone preservation) improvement. No functional vision benefit demonstrated.)
• PROGRESS-HF Phase 2 Trial: elamipretide in HFrEF (PMID 32068002, Journal of Cardiac Failure 2020)(71-patient double-blind RCT; neither 4 mg nor 40 mg elamipretide improved left ventricular end-systolic volume vs placebo at 4 weeks. Primary endpoint failed.)
• ReNEW Phase 3 in dry AMD (NCT06373731, ClinicalTrials.gov)(313 enrolled, active and not recruiting, no results posted.)
• EMBRACE-STEMI Phase 2a Trial: elamipretide in anterior STEMI (PMID 26586786, European Heart Journal 2016)(Phase 2a multicenter RCT by Gibson et al.; IV elamipretide during primary PCI did not reduce myocardial infarct size vs placebo. Primary endpoint failed.)
• Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF (PMC12841679, IJMS January 2026)(Rodent HFpEF model (obese ZSF1 rats, 12 weeks). Elamipretide modestly improved complex I and II respiration; mitochondrial ultrastructure, cardiolipin composition, and tafazzin expression unchanged. No functional or structural cardiac benefit observed. Reinforces the mechanistic-signal-without-functional-translation pattern seen in human trials.)
• FORZINITY (elamipretide) prescribing information, DailyMed, revised 9/2025(dose table)
• A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med 2021. PMID 33077895(dose table)
• Karaa A et al. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle 2020;11:909-918. PMID 32096613(dose table)
• Karaa A et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology 2023;101:e238-e252. PMID 37268435(dose table)
• PROGRESS-HF phase 2 trial of elamipretide in heart failure with reduced ejection fraction. J Card Fail 2020. PMID 32068002(dose table)
• ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration. Ophthalmol Sci 2025. PMID 39605874(dose table)